As EPR is also enhanced in many cardiovascular disease patients, the result of the present study also implies potential clinical implications of chronically targeting P2X3 signalling in cardiovascular disease with regard to other scenarios where the EPR is exaggerated. Here, P2RX3 is linked to cardiovascular disorder.